Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products
Rafarma Pharmaceuticals announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation. The new products are Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Sodium Para-Aminosalicilate is a tablet with a time release cover. The current dosage…